Literature DB >> 29253460

MicroRNA-31-3p Is Involved in Substance P (SP)-Associated Inflammation in Human Colonic Epithelial Cells and Experimental Colitis.

Kai Fang1, Ivy Ka Man Law1, David Padua1, Aristea Sideri1, Vanessa Huang1, Christopher G Kevil2, Dimitrios Iliopoulos3, Charalabos Pothoulakis4.   

Abstract

Substance P (SP) mediates colitis. SP signaling regulates the expression of several miRNAs, including miR-31-3p, in human colonocytes. However, the role of miR-31-3p in colitis and the underlying mechanisms has not been elucidated. We performed real-time PCR analysis of miR-31-3p expression in human colonic epithelial cells overexpressing neurokinin-1 receptor (NCM460 NK-1R) in response to SP stimulation and in NCM460 cells after IL-6, IL8, tumor necrosis factor (TNF)-α, and interferon-γ exposure. Functions of miR-31-3p were tested in NCM460-NK-1R cells and the trinitrobenzene sulfonic acid (TNBS) and dextran sodium sulfate (DSS) models of colitis. Targets of miRNA-31-3p were confirmed by Western blot analysis and luciferase reporter assay. Jun N-terminal kinase inhibition decreased SP-induced miR-31-3p expression. miR-31-3p expression was increased in both TNBS- and DSS-induced colitis and human colonic biopsies from ulcerative colitis, compared with controls. Intracolonic administration of a miR-31-3p chemical inhibitor exacerbated TNBS- and DSS-induced colitis and increased colonic TNF-α, CXCL10, and chemokine (C-C motif) ligand 2 (CCL2) mRNA expression. Conversely, overexpression of miR-31-3p ameliorated the severity of DSS-induced colitis. Bioinformatic, luciferase reporter assay, and Western blot analyses identified RhoA as a target of miR-31-3p in NCM460 cells. Constitutive activation of RhoA led to increased expression of CCL2, IL6, TNF-α, and CXCL10 in NCM460-NK-1R cells on SP stimulation. Our results reveal a novel SP-miR-31-3p-RhoA pathway that protects from colitis. The use of miR-31-3p mimics may be a promising approach for colitis treatment.
Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29253460      PMCID: PMC5840489          DOI: 10.1016/j.ajpath.2017.10.023

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

Review 1.  Tumor necrosis factor inhibitors for inflammatory bowel disease.

Authors:  Ole Haagen Nielsen; Mark Andrew Ainsworth
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

2.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.

Authors:  B L Bennett; D T Sasaki; B W Murray; E C O'Leary; S T Sakata; W Xu; J C Leisten; A Motiwala; S Pierce; Y Satoh; S S Bhagwat; A M Manning; D W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  Neurokinin-1 (NK-1) receptor is required in Clostridium difficile- induced enteritis.

Authors:  I Castagliuolo; M Riegler; A Pasha; S Nikulasson; B Lu; C Gerard; N P Gerard; C Pothoulakis
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

4.  Temporal genome expression profile analysis during t-cell-mediated colitis: identification of novel targets and pathways.

Authors:  Kai Fang; Songlin Zhang; John Glawe; Matthew B Grisham; Christopher G Kevil
Journal:  Inflamm Bowel Dis       Date:  2011-12-16       Impact factor: 5.325

5.  Substance P-stimulated interleukin-8 expression in human colonic epithelial cells involves Rho family small GTPases.

Authors:  Dezheng Zhao; Sabina Kuhnt-Moore; Huiyan Zeng; Amy Pan; Jack S Wu; Simos Simeonidis; Mary P Moyer; Charalabos Pothoulakis
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

6.  Metalloproteinases and transforming growth factor-alpha mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes.

Authors:  Hon-Wai Koon; Dezheng Zhao; Xi Na; Mary P Moyer; Charalabos Pothoulakis
Journal:  J Biol Chem       Date:  2004-08-19       Impact factor: 5.157

7.  Antiinflammatory effect of Rho kinase blockade via inhibition of NF-kappaB activation in rheumatoid arthritis.

Authors:  Ya He; Hanshi Xu; Liuqin Liang; Zhongping Zhan; Xiuyan Yang; Xueqing Yu; Yujin Ye; Lin Sun
Journal:  Arthritis Rheum       Date:  2008-11

8.  Crohn's disease-associated adherent invasive Escherichia coli modulate levels of microRNAs in intestinal epithelial cells to reduce autophagy.

Authors:  Hang Thi Thu Nguyen; Guillaume Dalmasso; Stefan Müller; Jessica Carrière; Frank Seibold; Arlette Darfeuille-Michaud
Journal:  Gastroenterology       Date:  2013-10-19       Impact factor: 22.682

9.  Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: lithium chloride purification, a rapid and efficient technique to purify RNA.

Authors:  Emilie Viennois; Fengyuan Chen; Hamed Laroui; Mark T Baker; Didier Merlin
Journal:  BMC Res Notes       Date:  2013-09-08

10.  Identification of a novel substance P (SP)-neurokinin-1 receptor (NK-1R) microRNA-221-5p inflammatory network in human colonic epithelial cells.

Authors:  Kai Fang; Aristea Sideri; Ivy Ka Man Law; Kyriaki Bakirtzi; Christos Polytarchou; Dimitrios Iliopoulos; Charalabos Pothoulakis
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-09-01
View more
  9 in total

1.  Knockout of the Tachykinin Receptor 1 in the Mdr2-/- (Abcb4-/-) Mouse Model of Primary Sclerosing Cholangitis Reduces Biliary Damage and Liver Fibrosis.

Authors:  Ludovica Ceci; Heather Francis; Tianhao Zhou; Thao Giang; Zhihong Yang; Fanyin Meng; Nan Wu; Lindsey Kennedy; Konstantina Kyritsi; Vik Meadows; Chaodong Wu; Suthat Liangpunsakul; Antonio Franchitto; Amelia Sybenga; Burcin Ekser; Romina Mancinelli; Paolo Onori; Eugenio Gaudio; Shannon Glaser; Gianfranco Alpini
Journal:  Am J Pathol       Date:  2020-07-23       Impact factor: 4.307

Review 2.  Current Knowledge on Exosome Biogenesis, Cargo-Sorting Mechanism and Therapeutic Implications.

Authors:  Shenmin Xie; Qin Zhang; Li Jiang
Journal:  Membranes (Basel)       Date:  2022-05-06

Review 3.  Role of MicroRNA in Inflammatory Bowel Disease: Clinical Evidence and the Development of Preclinical Animal Models.

Authors:  Kanika Suri; Jason A Bubier; Michael V Wiles; Leonard D Shultz; Mansoor M Amiji; Vishnu Hosur
Journal:  Cells       Date:  2021-08-26       Impact factor: 7.666

Review 4.  miRNAs Can Affect Intestinal Epithelial Barrier in Inflammatory Bowel Disease.

Authors:  Xiangjun Xiao; Xiangbing Mao; Daiwen Chen; Bing Yu; Jun He; Hui Yan; Jianping Wang
Journal:  Front Immunol       Date:  2022-04-13       Impact factor: 8.786

5.  CSE/H2S ameliorates colitis in mice via protection of enteric glial cells and inhibition of the RhoA/ROCK pathway.

Authors:  Song Wang; Yanyu Ding; Wenjun Jiang
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

6.  MicroRNA-31-3p/RhoA signaling in the dorsal hippocampus modulates methamphetamine-induced conditioned place preference in mice.

Authors:  Hongyan Qian; Qing Shang; Min Liang; Baoyao Gao; Jing Xiao; Jing Wang; Axiang Li; Canyu Yang; Jianmin Yin; Gang Chen; Tao Li; Xinshe Liu
Journal:  Psychopharmacology (Berl)       Date:  2021-07-27       Impact factor: 4.530

7.  MiR-21 in Substance P-induced exosomes promotes cell proliferation and migration in human colonic epithelial cells.

Authors:  Kyriaki Bakirtzi; Ivy Ka Man Law; Kai Fang; Dimitrios Iliopoulos; Charalabos Pothoulakis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-09-23       Impact factor: 4.871

8.  Substance P induces sympathetic immune response in the contralateral eye after the first eye cataract surgery in type 2 diabetic patients.

Authors:  Xianhui Gong; Yueping Ren; Xiuxiu Fang; Junyong Cai; E Song
Journal:  BMC Ophthalmol       Date:  2020-08-18       Impact factor: 2.209

Review 9.  MicroRNA Biomarkers in IBD-Differential Diagnosis and Prediction of Colitis-Associated Cancer.

Authors:  Jaslin P James; Lene Buhl Riis; Mikkel Malham; Estrid Høgdall; Ebbe Langholz; Boye S Nielsen
Journal:  Int J Mol Sci       Date:  2020-10-24       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.